博文
Lecanemab用于早期阿尔茨海默病
||
Lecanemab用于早期阿尔茨海默病
可溶性和不溶性聚集淀粉样β蛋白(Aβ)的积聚可能启动或加强阿尔茨海默病的病理过程。Lecanemab是一种人源化IgG1单克隆抗体，以高亲和力结合Aβ可溶性原纤维，正在早期阿尔茨海默病患者中进行测试。
https://blog.sciencenet.cn/blog-55647-1367442.html
http://www.pubmedplus.cn/P/SearchQuickResult?wd=e9d47af9-98de-413c-a479-dec82bddb8b6
| 01. | 无法确认 | 4 篇 | 19.048% |
| 02. | 2022 | 7 篇 | 33.333% |
| 03. | 2021 | 2 篇 | 9.524% |
| 04. | 2020 | 2 篇 | 9.524% |
| 05. | 2018 | 1 篇 | 4.762% |
| 06. | 2016 | 1 篇 | 4.762% |
| 01. | alzheimers res ther | 4 篇 | 19.048% |
| 02. | j prev alzheimers dis | 2 篇 | 9.524% |
| 03. | neurol ther | 2 篇 | 9.524% |
| 04. | rev neurol (paris) | 2 篇 | 9.524% |
| 05. | alzheimers dement | 1 篇 | 4.762% |
| 06. | cpt pharmacometrics syst pharmacol | 1 篇 | 4.762% |
| 07. | curr opin psychiatry | 1 篇 | 4.762% |
| 08. | expert opin biol ther | 1 篇 | 4.762% |
| 09. | inn med (heidelb) | 1 篇 | 4.762% |
| 10. | mol cell neurosci | 1 篇 | 4.762% |
| 01. | 美国 | 11 篇 | 52.381% |
| 02. | 瑞典 | 4 篇 | 19.048% |
| 03. | 英国 | 4 篇 | 19.048% |
| 04. | 法国 | 3 篇 | 14.286% |
| 05. | 巴西 | 1 篇 | 4.762% |
| 06. | 日本 | 1 篇 | 4.762% |
| 07. | 意大利 | 1 篇 | 4.762% |
| 没有聚类出数据 |
| 01. | Alzheimer Disease | 10 篇 | 47.619% |
| 02. | Humans | 10 篇 | 47.619% |
| 03. | Amyloid beta-Peptides | 7 篇 | 33.333% |
| 04. | Antibodies, Monoclonal | 6 篇 | 28.571% |
| 05. | Brain | 5 篇 | 23.810% |
| 06. | Antibodies, Monoclonal, Humanized | 4 篇 | 19.048% |
| 07. | Amyloid | 3 篇 | 14.286% |
| 08. | Aged | 2 篇 | 9.524% |
| 09. | Biomarkers | 2 篇 | 9.524% |
| 10. | Clinical Trials as Topic | 2 篇 | 9.524% |
https://blog.sciencenet.cn/blog-280034-1367496.html
上一篇：治疗抑郁症的电子游戏与心理咨询效果
下一篇：智慧医疗
